Lilly(Eli) & Company
NYSE: LLY
$753.72
+$11.37 (+1.5%)
Closing Price on January 22, 2025
LLY Articles
The three major U.S. stock indexes opened higher this morning following a better-than-expected PMI reading from China (more coverage here) that was mostly untempered by lower-than-expected PMI...
Published:
Last Updated:
Eli Lilly (NYSE: LLY) this morning reported disappointing third-quarter results as generic drugs took a toll on its sales. The Indianapolis-based drug maker posted adjusted earnings per share (EPS)...
Published:
The three major U.S. stock indexes opened lower this morning and remained in negative territory all day. The decline is down to weak earnings from many U.S. firms reporting results today. In Europe,...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Tuesday. Apple Inc. (NASDAQ: AAPL) reiterated Outperform with $750 target at...
Published:
Last Updated:
Eli Lilly & Co. (NYSE: LLY) is confirming prior news showing that late-stage trial data analysis showed the the primary endpoints in cognitive and functional were not met in the two Phase 3,...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Wednesday. Activision Blizzard Inc. (NASDAQ: ATVI) started as Buy at Jefferies....
Published:
Last Updated:
The three major U.S. stock indexes opened flat to higher this morning but picked up some buying steam after the first hour or so of trading. In Europe the president of Germany’s Bundesbank said...
Published:
Last Updated:
Jon OggThese are the top analyst calls of upgrades, downgrades and initiations we have seen from Wall St. research calls this Monday morning. Amazon.com Inc. (NASDAQ: AMZN) reiterated Buy with $264...
Published:
Last Updated:
Drugmaker Eli Lilly & Co. (NYSE: LLY) announced this morning that the company’s solanezumab treatment for Alzheimer’s disease failed to meet both the cognitive and functional endpoints in...
Published:
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall St. research calls this Monday morning. Annaly Capital Management Inc. (NYSE: NLY) cut to Underperform...
Published:
Last Updated:
The three major US stock indexes opened mixed this morning with the Nasdaq Composite slightly negative on an unexpectedly weak earnings report from Apple Inc. (NASDAQ: AAPL) (more coverage here). A...
Published:
Last Updated:
Surging growth of its Cymbalta depression treatment helped Eli Lilly & Co. (NYSE: LLY) beat Wall St.’s earnings expectations. But generic rivals to Plavix, other drugs hurt Bristol-Myers Squibb...
Published:
The three major US stock indexes opened roughly flat this morning as Spanish 10-year bond yields rose to 7.5% and Moody’s cut Germany’s outlook to ‘negative’ after the markets closed last...
Published:
Last Updated:
A new treatment for Alzheimer’s disease from Pfizer Inc. (NYSE: PFE) and partner Elan Corp. plc (NYSE: ELN) has failed a late-stage trial in patients with mild-to-moderate cases of the disease and...
Published:
Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for the first quarter of 2012. The top five sellers include drugs from Bristol-Myers...
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.